S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Novozymes A/S (NVZMY) Stock Forecast, Price & News

+0.32 (+0.52%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
14,993 shs
Average Volume
18,653 shs
Market Capitalization
$14.15 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

Novozymes A/S logo

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.


Analysts Set Novozymes A/S (OTCMKTS:NVZMY) PT at $425.00
Novozymes A/S (NVZMY)
Group financial statement and annual report for 2021
CE or NVZMY: Which Is the Better Value Stock Right Now?
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.38 billion
Cash Flow
$2.27 per share
Book Value
$8.51 per share


Net Income
$500.53 million
Pretax Margin




Free Float
Market Cap
$14.15 billion
Not Optionable

Company Calendar

Last Earnings
Ex-Dividend for 4/5 Dividend
Dividend Payable
Fiscal Year End

Social Links


Overall MarketRank

1.86 out of 5 stars

Analyst Opinion: 3.1Community Rank: 3.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Novozymes A/S (OTCMKTS:NVZMY) Frequently Asked Questions

Is Novozymes A/S a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S
or view top-rated stocks.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 7,300 shares, a decline of 53.5% from the April 30th total of 15,700 shares. Based on an average daily volume of 32,400 shares, the days-to-cover ratio is presently 0.2 days.
View Novozymes A/S's Short Interest

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) issued its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.42 EPS for the quarter, hitting analysts' consensus estimates of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a trailing twelve-month return on equity of 27.43% and a net margin of 21.04%.
View Novozymes A/S's earnings history

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S declared a dividend on Tuesday, March 15th. Investors of record on Friday, March 18th will be given a dividend of $0.567 per share on Tuesday, April 5th. This represents a yield of 0.95%. The ex-dividend date is Thursday, March 17th.
View Novozymes A/S's dividend history

Is Novozymes A/S a good dividend stock?

Novozymes A/S pays an annual dividend of $0.55 per share and currently has a dividend yield of 0.89%. The dividend payout ratio of Novozymes A/S is 31.61%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 29.89% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

What price target have analysts set for NVZMY?

8 brokerages have issued 12 month price targets for Novozymes A/S's shares. Their forecasts range from $360.00 to $490.00. On average, they expect Novozymes A/S's share price to reach $425.00 in the next year. This suggests a possible upside of 582.5% from the stock's current price.
View analysts' price targets for Novozymes A/S
or view top-rated stocks among Wall Street analysts.

Who are Novozymes A/S's key executives?
Novozymes A/S's management team includes the following people:
  • Ms. Ester Baiget, Pres & CEO (Age 51, Pay $2.29M)
  • Mr. Lars Green M.Sc., MSc, Exec. VP & CFO (Age 55, Pay $2.24M)
  • Ms. Graziela Chaluppe dos Santos Malucelli, COO and Exec. VP of Operations, Supply & Quality (Age 49)
  • Mr. Tobias Cornelius Bjorklund, Head of Investor Relations
  • Mr. Tue Micheelsen, VP of Global Sales & Marketing
  • Mr. Morten Enggaard Rasmussen, Exec. VP of People, Sustainability & Brand (Age 46)
  • Mr. Pedro Luiz Fernandes, Head of Corp. Affairs & Sustainability - Novozymes Latin America
  • Mr. Anders Lund, Exec. VP of Consumer Biosolutions (Age 49)
  • Mr. Sebastian Søderberg, VP and Head of New Bus. Devel. - Incubations & Acquisitions
  • Ms. Tina Sejersgaard Fanoe, Exec. VP of Agriculture & Industrial Biosolutions (Age 53)
What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $62.27.

How much money does Novozymes A/S make?

Novozymes A/S has a market capitalization of $14.15 billion and generates $2.38 billion in revenue each year. The biotechnology company earns $500.53 million in net income (profit) each year or $1.74 on an earnings per share basis.

How many employees does Novozymes A/S have?

Novozymes A/S employs 6,527 workers across the globe.

Does Novozymes A/S have any subsidiaries?

The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.

When was Novozymes A/S founded?

Novozymes A/S was founded in 2000.

What is Novozymes A/S's official website?

The official website for Novozymes A/S is www.novozymes.com.

How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at (454) 446-0000, via email at [email protected], or via fax at 45-4446-9999.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.